Blood-cancer treatment still lacks functional context. We’re building it.
MYCancer engineers patient-derived bone-marrow models to reveal ex vivo drug-response patterns within a target 72-hour workflow - supporting translational research today and the development of future regulated precision-oncology tools.
Our current platform is intended exclusively for research and translational R&D.
Our Research Platform
Meet the MYLeukaemia Bone-Marrow-on-Chip Research Platform: an organ-on-chip system designed to model selected features of the human bone-marrow microenvironment and support controlled ex vivo studies of blood-cancer cells under defined experimental conditions.
Discover our innovative marrow-avatar platform.
How it Works
Under approved research protocols, a small peripheral-blood or bone-marrow sample is processed in our central lab. We isolate viable leukaemia cells and introduce them into MYLeukaemia chipset - our bioengineered bone-marrow-avatar research model.
Cells are exposed to protocol-defined treatment regimens. Flow cytometry and imaging quantify ex vivo response patterns and generate a concise research heatmap with quality-control flags.
The resulting research output may include experimental response measurements, quality-control information, protocol details and study-specific observations. It is not a diagnostic report, does not rank treatments for an individual patient and must not be used for patient management or treatment selection at this stage of development.
Turning complex blood-cancer biology into structured functional evidence.
1
> 100,000 leukemic cells are isolated and integrated in a sophisticated MYLeukaemia Organ-on-Chip Chipset
Isolate Live Cells from protocol-defined blood specimens
2
3
Patient-personalized Bone Marrow Research Model
Functional Precision Oncology sensitivity Testing
Drug testing for clinically used drug regimens ID's Leukaemia’ funcional drivers & rank drug sensitivity by FC & other tools.
Patient-derived blasts colonize a 3D, vascularised Organ-on-Chip, recreating the patient’s bone marrow Leukemic niche within 24h.
For Research Use Only. MYLeukaemia is an R&D-stage platform and is not CE-marked as an in vitro diagnostic medical device. It is not intended for diagnosis, patient management or treatment selection at this point of development.
What Makes Our MYLeukaemia Chipset Unique
A streamlined workflow designed to generate structured functional-response data in approximately 72 hours.
72-hour decision support
Unmatched native marrow-like niche bioengineering for clinically relevant, context-aware drug-response readouts.
Human Bone-Marrow avatars
Functional precision (ex vivo)
Functionally tests patient-derived cells beforehand to complement Standard-of-Care diagnostics (cytogenetics, flow, PCR, NGS) for truly personalized therapy choices.
Minimal-burden sampling
Just +5 mL added to routine peripheral or BM draws; no extra procedure.
Clear heatmap, ranked therapy options, QC flags; available clinical trials; in a simple & concise PDF report
Tumour-board-ready outputs
Pilot-ready & IVDR-aware
TRL4 with MVP on multiple AML cell lines; 20-patient pilot next; CE-IVD horizon ~36 months.
CEO | Hugo Caires, PhD
Project Leader with +12 years of experience in Tissue Engineering, Cancer & Clinical Research in Leukaemia. +20 papers in top journals with +5000 citations.
CBO | Hugo Prazeres, MBA, PhD
+30 papers in top journals, Co-founder of 3+ biotech companies. Consultant on CE marking and IVD Medical Devices.
COO | Diana Sousa, MSc
Pharmacist with +11 years of experience in sales, community healthcare & health economics, bridging clinical insight with real-world commercialization.
Complementary Expertise. One Founding Team.
Our trusted partners & supporters
From recognition on international stages to competitive grant funding and clinical alliances, MYLeukaemia has earned validation at every step. These achievements form the foundation for our next chapter: transforming personalised therapy selection for blood cancer patients.
+2
peer-reviewed articles published
+€70k
capital raised for R&D
+2
years of R&D in top institutions
Awards
Early validation. Execution mode on.
Follow us on LinkedIN
MYCancer
26 November, 2025
🎉 Yesterday, something happened that I never imagined I would write on LinkedIn.
We walked into the EIT Jumpstarter Grand Final in Budapest as a small deeptech team from Madeira -
a remote Atlantic island that rarely appears on Europe’s innovation radar.
And we walked out with two awards:
🏆 1st Place – Health Cohort
🌍 Best Outermost Region Team (...)
MYCancer
17 July, 2025
We made the top 7. 🧬
Out of many groundbreaking startups across Europe, MYLeukaemia Project is heading to the finals of the EP PerMed Venture Creator.
Still processing (...)
MYCancer
13 May, 2025
He was in his 30s.
Same age as me.
I didn’t know his name.
I just knew his blood.
He was my first ever blood cancer case.
Intermediate risk. Good initial response.
Everything said it should work (...)
MYCancer. All rights reserved. © 2026
Subscribe to our newsletter
No Spam. Just occasional product updates & events.
Company
About
Careers
News & Press
Contact
Campus da Penteada, 9020-105 Funchal, Portugal ·
How to Join Us:
Start a Pilot
Request Study Design
Request Data Room
For Research Use Only. MYLeukaemia is an R&D-stage bone-marrow-on-chip platform. It is not CE-marked as an in vitro diagnostic medical device and is not intended for diagnosis, clinical assessment, patient management or treatment selection. Any future clinical use is subject to analytical and clinical validation and the applicable regulatory conformity route.
